SCHEMBL16123426

SCHEMBL16123426

CNc1nc(N)nc(NCCCNc2c3ccc(Cl)cc3nc3ccc(OC)cc23)n1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBNL1 Q9NR56 1/20 0.85
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
ADORA2A P29274 1/20 0.61
GSR P00390 7/20 0.57
NPC1 O15118 1/20 0.49
USP2 O75604 1/20 0.49
PRNP P04156 1/20 0.49
CHRM2 P08172 1/20 0.49
CHRM4 P08173 1/20 0.49
ABCB1 P08183 1/20 0.49
HTR1A P08908 1/20 0.49
CHRM5 P08912 1/20 0.49
ADRA2A P08913 1/20 0.49
CHRM1 P11229 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
CHRM3 P20309 1/20 0.49
DRD1 P21728 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7880398 0.87 MEN1 (0.79) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL7869225 0.84 MBNL1 (0.81) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL18163841 0.83 ADORA2A (0.80) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL20087053 0.83 MBNL1 (0.80) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL20087077 0.83 MBNL1 (0.80) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL20087027 0.83 MBNL1 (0.80) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL7875793 0.83 ADORA2A (0.83) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL29375789 0.83 ADORA2A (0.83) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL23795497 0.82 MBNL1 (0.75) MBNL1MEN1KMT2ATDP1ADORA2A
SCHEMBL12057934 0.82 ADORA2A (0.78) MBNL1MEN1KMT2ATDP1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382215-B2 Therapeutic methods and agents for treating myotonic dystrophy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-07-05 US disclosed
US-20140288080-A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288080-A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY POLRMT, SMN1; SMN2, MTPN MBNL1 10/4885MEN1 3548/4885KMT2A 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.